COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
Clinical trial NCT04852978 · COMPLETED
Trial details
- NCT number
- NCT04852978
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-29
- Primary completion
- 2022-11-21
- Enrollment
- 295
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.